martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 17, 2026

New Fed Chair Kevin Warsh Wants to Blow Up the Playbook That's Kept Stocks Rising for 15 Years. Here's What Investors Should Do Now.

View original at nasdaq.com
New Fed Chair Kevin Warsh Wants to Blow Up the Playbook That's Kept Stocks Rising for 15 Years. Here's What Investors Should Do Now. Key Points New Fed chair Kevin Warsh wants to shrink the Fed's balance sheet…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A shrinking Fed balance sheet won't be catastrophic; markets will adapt over time to any changes under Warsh's leadership.

    60% confidence
  • Investors should reduce exposure to QE-dependent stocks, increase exposure to financials like Berkshire Hathaway, shift bonds to shorter durations, build cash, and maintain a long-term perspective.

    60% confidence
  • Warsh's desire for a smaller Fed balance sheet means that the Fed Put is somewhat deeper out of the money but remains present in the event of a real crisis.

    60% confidence
  • The Fed's balance sheet disproportionately helps those with financial assets.

    60% confidence
  • Stock Advisor has a total average return of 993% compared to 207% for the S&P 500.

    60% confidence
  • Kevin Warsh wants to aggressively reduce the Fed's balance sheet and believes the Fed should use interest rates rather than its balance sheet as a policy tool.

    60% confidence
  • Tech stocks with sky-high earnings multiples could see their valuations reduced as higher discount rates are applied to their projected future earnings if the Fed reduces its balance sheet.

    60% confidence

Data points we hold from this source

S&P 500 Index Fund · benchmark return207 percent
S&P 500 Index Fund · price appreciation6 multiple_x
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com